Compare NTR & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTR | RMD |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | Canada | United States |
| Employees | N/A | 10600 |
| Industry | Agricultural Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 28.4B |
| IPO Year | 2018 | N/A |
| Metric | NTR | RMD |
|---|---|---|
| Price | $68.73 | $193.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 10 |
| Target Price | $75.45 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 2.7M | 1.6M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.95% | 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.03 | $10.60 |
| Revenue Next Year | N/A | $7.41 |
| P/E Ratio | ★ $18.99 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.03 | $180.27 |
| 52 Week High | $85.36 | $293.81 |
| Indicator | NTR | RMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.90 |
| Support Level | N/A | $190.25 |
| Resistance Level | N/A | $197.41 |
| Average True Range (ATR) | 0.00 | 6.01 |
| MACD | 0.00 | -0.82 |
| Stochastic Oscillator | 0.00 | 21.22 |
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.